Macular infarction following intravitreal bevacizumab for treatment of central retinal vein occlusion.

Loh Shan B. Leung, Ruwan A. Silva, Mark S. Blumenkranz, Harry W. Flynn, Steven R. Sanislo

Research output: Contribution to journalArticle

5 Scopus citations

Abstract

Bevacizumab, a monoclonal antibody against vascular endothelial growth factor (VEGF), is widely used for the treatment of macular edema associated with central retinal vein occlusion (CRVO). The authors present a series of three patients with CRVO who suffered apparent macular infarction within weeks of intravitreal administration of bevacizumab. Of the nearly 200 patients undergoing intravitreal injections of bevacizumab for this indication over a surveillance period of 3 years, this event occurred in three patients. This has not been described in the natural history of the disease and is associated with poor visual outcomes.

ASJC Scopus subject areas

  • Surgery
  • Ophthalmology

Fingerprint Dive into the research topics of 'Macular infarction following intravitreal bevacizumab for treatment of central retinal vein occlusion.'. Together they form a unique fingerprint.

  • Cite this